The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 4SC’s resminostat (Kinselby) for cutaneous T-cell lymphoma (CTCL). Resminostat is an orally administered class I, IIb and IV histone deacetylase (HDAC) inhibitor that potentially offers an approach to treating different kinds of cancer. The company demonstrated that resminostat is… Read More
The US Food and Drug Administration (FDA) has granted fast track designation to Mythic Therapeutics’ investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression. The designation for Mythic, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for… Read More
The National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (DLd) for untreated multiple myeloma (MM) for routine use on the NHS in England and Wales. The therapy is now recommended within an NHS setting for the treatment of adults with… Read More
Leucid Bio has been granted clinical trial authorisation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid tumours. The open-label, single patient cohort ascending… Read More
HKG Epitherapeutics is a biotechnology company developing novel tools for the early detection of cancer and promoting healthy aging. Founder Dr Moshe Szyf Founder shares the potential of harnessing precision medicine. Embarking on a new era of medicine The advent of genomics has ushered in the era of personalised medicine,… Read More
Umoja Biopharma has revealed data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the company’s VivoVec platform. The data include results from the first four NHPs treated in an ongoing study… Read More
On 13 September 2023, the American Association for Cancer Research (AACR) released the AACR Cancer Progress Report 2023: Advancing the Frontiers of Cancer Science and Medicine. This report chronicles how basic, translational, clinical cancer research, and cancer-related population sciences — supported by federal investments in the National Institutes of Health… Read More
The regulation of cellular bioenergetics is recognised as a key driver of cancer cell proliferation. Identifying key pathways that modulate bioenergetic metabolism is a promising strategy for developing novel therapeutics for cancer treatment. Discover more in this new App Note from Agilent entitled ‘Rapid Bioenergetic Functional Screening of Anticancer Drug… Read More
The regulation of cellular bioenergetics is recognised as a key driver of cancer cell proliferation. Identifying key pathways that modulate bioenergetic metabolism is a promising strategy for developing novel therapeutics for cancer treatment. In this App Note you will learn: How the Agilent Seahorse XF Real Time ATP rate assay… Read More
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has announced data from a pre-defined interim analysis related to the lung cohort of the Phase II basket trial (IOB-022/KN-D38) with IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy as… Read More
Moderna and Immatics have announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high, unmet medical need. This broad multi-platform collaboration will leverage the scientific expertise and core operational capabilities of both companies, combining Immatics’ TCR platform with Moderna’s… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Shelley… Read More
The first quadruplex-edited, allogeneic CAR-T cell therapy candidate has entered clinical trials in the US. The first patient has been treated with Beam Therapeutics’ BEAM-201 as part of a Phase I/II clinical study for the treatment of relapsed/refractory T-cell acute lymphoblastic leukaemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL). Read More
In the Phase III innovaTV 301 trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, Tivdak (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (OS). An independent data monitoring committee determined that OS crossed… Read More
DDW's Diana Spencer highlights five key clinical studies taking a new therapeutic approach to childhood cancers. Over 100 subtypes of childhood cancer exist today and it represents the most common cause of disease-related death in children. However, despite the fact that children’s response to adult cancer drugs is often poor,… Read More
A new whitepaper has introduced the concept of ‘cross-over’ options in cancer clinical trials, as a way to make trials more patient-centric in design. ‘Cross-over arms in oncology clinical trials: An important consideration for patients’ was published by the Cholangiocarcinoma Foundation (CCF) with the aim of… Read More
